nach oben

Quality of Life Research

Erschienen in:

07.11.2015

Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice

verfasst von: Szu-Chun Yang, Wu-Wei Lai, Tzuen-Ren Hsiue, Wu-Chou Su, Cheng-Kuan Lin, Jing-Shiang Hwang, Jung-Der Wang

Erschienen in: Quality of Life Research | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study attempted to compare changes in the Quality-of-Life (QoL) scores after three different first-line anti-cancer treatments for advanced non-small cell lung cancer (NSCLC) in a real-world clinical setting.

Patients and methods

From May 2011 to December 2013, we prospectively measured the QoL scores of patients with locally advanced or metastatic NSCLC using the World Health Organization Quality-of-Life—Brief (WHOQOL-BREF) questionnaire. Each QoL measurement was matched by age and sex with one healthy referent from the National Health Interview Survey. Dynamic changes in patients’ QoL scores and major determinants were repeatedly assessed by construction of a mixed-effects model to adjust for possible confounders.

Results

A total of 336 patients with 577 QoL measurements related to first-line anti-cancer treatments were enrolled. Performance status was the most important predictor of QoL scores in all domains after controlling for potential confounders. With age- and sex-matched healthy subjects as the reference, patients treated with gemcitabine + platinum showed significantly lower scores in multiple physical and psychological domain items in the WHOQOL-BREF. However, pemetrexed + platinum and gefitinib/erlotinib affected patients’ QoL scores in ‘energy/fatigue’ and ‘daily activities’ with smaller magnitudes, and the scores appeared to improve after 3–4 months of treatment.

Conclusions

Patients receiving gemcitabine + platinum as first-line anti-cancer treatment for advanced NSCLC experienced relatively poor QoL scores throughout treatment course. Studies to develop a real-time computerized system automatically updating the mixed-effects model for QoL to facilitate participatory clinical decision making by physicians, patients, and their families merit further research.

Nur mit Berechtigung zugänglich

Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893–2917.CrossRefPubMed

American Cancer Society. (2010). Cancer Facts and Figures 2010. Atlanta: American Cancer Society.

Claassens, L., van Meerbeeck, J., Coens, C., Quinten, C., Ghislain, I., Sloan, E. K., et al. (2011). Health-related quality of life in non-small-cell lung cancer: An update of a systemic review on methodological issues in randomized controlled trials. Journal of Clinical Oncology, 29, 2104–2120.CrossRefPubMedPubMedCentral

Lee, L. J., Chung, C. W., Chang, Y. Y., Lee, Y. C., Yang, C. H., Liou, S. H., et al. (2011). Comparison of the quality of life between patients with non-small-cell lung cancer and healthy controls. Quality of Life Research, 20, 415–423.CrossRefPubMed

Lin, C. Y., Yang, S. C., Lai, W. W., Su, W. C., & Wang, J. D. (2015). Rasch models suggested the satisfactory psychometric properties of the World Health Organization Quality of Life—Brief among lung cancer patients. Journal of Health Psychology,. doi:10.1177/1359105315603474.

Chen, G., Feng, J., Zhou, C., Wu, Y. L., Liu, X. Q., Wang, C., et al. (2013). Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomized, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Annals of Oncology, 24, 1615–1622.CrossRefPubMed

Grønberg, B. H., Bremnes, R. M., Fløtten, Ø., Amundsen, T., Brunsvig, P. F., Hjelde, H. H., et al. (2009). Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 27, 3217–3224.CrossRefPubMed

Tazaki, M., Nakane, Y., Endo, T., Kakikawa, F., Kano, K., Kawano, H., et al. (1998). Results of a qualitative and field study using the WHOQOL instrument for cancer patients. Japanese Journal of Clinical Oncology, 28, 134–141.CrossRefPubMed

Mohan, A., Mohan, C., Pathak, A. K., Pandey, R. M., & Guleria, R. (2007). Impact of chronic obstructive pulmonary disease on respiratory status and quality of life in newly diagnosed patients with lung cancer. Respirology, 12, 240–247.CrossRefPubMed

10.

Yao, G., Chung, C. W., Yu, C. F., & Wang, J. D. (2002). Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. Journal of the Formosan Medical Association, 101, 342–351.PubMed

11.

The WHOQOL Group, Programme on Mental Health, WHO. (1996). WHOQOL-BREF introduction, administration, scoring and generic version of the assessment. Geneva, Switzerland: World Health Organization.

12.

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., et al. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 13, 239–246.CrossRefPubMed

13.

Leighl, N. B. (2012). Treatment paradigms for patients with metastatic non-small-cell lung cancer: First-, second-, and third- line. Current Oncology, 19, S52–S58.CrossRefPubMedPubMedCentral

14.

Hwang, J. S., & Wang, J. D. (2004). Integrating health profile with survival for quality of life assessment. Quality of Life Research, 13, 1–10.CrossRefPubMed

15.

Phungrassami, T., Katikarn, R., Watanaarepornchai, S., & Sangtawan, D. (2004). Quality of life assessment in radiotherapy patients by WHOQOL-BREF-THAI: A feasibility study. Journal of the Medical Association of Thailand, 87, 1459–1465.PubMed

16.

Zimmermann, C., Burman, D., Swami, N., Krzyzanowska, M. K., Leighl, N., Moore, M., et al. (2011). Determinants of quality of life in patients with advanced cancer. Supportive Care in Cancer, 19, 621–629.CrossRefPubMed

17.

Lam, K., Chow, E., Zhang, L., Wong, E., Bedard, G., Fairchild, A., et al. (2013). Determinants of quality of life in advanced cancer patients with bone metastases undergoing palliative radiation treatment. Supportive Care in Cancer, 21, 3021–3030.CrossRefPubMed

18.

Jatoi, A., Novotny, P., Cassivi, S., Clark, M. M., Midthun, D., Patten, C. A., et al. (2007). Does marital status impact survival and quality of life in patients with non-small cell lung cancer? Observations from the Mayo Clinic lung cancer cohort. Oncologist, 12, 1456–1463.CrossRefPubMed

19.

Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., et al. (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 26, 3543–3551.CrossRefPubMed

20.

Scagliotti, G. V., Park, K., Patil, S., Rolski, J., Goksel, T., Martins, R., et al. (2009). Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. European Journal of Cancer, 45, 2298–2303.CrossRefPubMed

21.

Han, J. Y., Park, K., Kim, S. W., Lee, D. H., Kim, H. Y., Kim, H. T., et al. (2012). First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. Journal of Clinical Oncology, 30, 1122–1128.CrossRefPubMed

22.

Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X. Q., Wang, C., et al. (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicenter, open-label, randomized, phase 3 study. Lancet Oncology, 12, 735–742.CrossRefPubMed

23.

Wang, B. Y., Huang, J. Y., Cheng, C. Y., Lin, C. H., Ko, J., & Liaw, Y. P. (2013). Lung cancer and prognosis in Taiwan: A population-based cancer registry. Journal of Thoracic Oncology, 8, 1128–1135.CrossRefPubMed

24.

Sloan, J. A., Zhao, X., Novotny, P. J., Wampfler, J., Garces, Y., Clark, M. M., et al. (2012). Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. Journal of Clinical Oncology, 30, 1498–1504.CrossRefPubMedPubMedCentral

25.

Chen, J., Qi, Y., Wampfler, J. A., Jatoi, A., Garces, Y. I., Busta, A. J., et al. (2012). Effect of cigarette smoking on quality of life in small cell lung cancer patients. European Journal of Cancer, 48, 1593–1601.CrossRefPubMedPubMedCentral

Titel: Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice
verfasst von: Szu-Chun Yang
Wu-Wei Lai
Tzuen-Ren Hsiue
Wu-Chou Su
Cheng-Kuan Lin
Jing-Shiang Hwang
Jung-Der Wang
Publikationsdatum: 07.11.2015
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 6/2016
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-015-1174-5

Springer Medizin

Abstract

Purpose

Patients and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Using structural equation modeling to detect response shifts and true change in discrete variables: an application to the items of the SF-36

Using a retrospective pretest instead of a conventional pretest is replacing biases: a qualitative study of cognitive processes underlying responses to thentest items

The Guttman errors as a tool for response shift detection at subgroup and item levels

Health-related quality of life in Parkinson’s: impact of ‘off’ time and stated treatment preferences

Cardiff cardiac ablation patient-reported outcome measure (C-CAP): validation of a new questionnaire set for patients undergoing catheter ablation for cardiac arrhythmias in the UK

Quality of life in patients with chronic venous disease in Turkey: influence of different treatment modalities at 6-month follow-up